CN103974712A - 治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法 - Google Patents

治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法 Download PDF

Info

Publication number
CN103974712A
CN103974712A CN201280027349.3A CN201280027349A CN103974712A CN 103974712 A CN103974712 A CN 103974712A CN 201280027349 A CN201280027349 A CN 201280027349A CN 103974712 A CN103974712 A CN 103974712A
Authority
CN
China
Prior art keywords
alkyl
phenyl
alkenyl
optionally substituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280027349.3A
Other languages
English (en)
Chinese (zh)
Inventor
J·莫斯卡尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NORTHWEST UNIVERSITY
Original Assignee
NORTHWEST UNIVERSITY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NORTHWEST UNIVERSITY filed Critical NORTHWEST UNIVERSITY
Priority to CN201711451914.XA priority Critical patent/CN108283712A/zh
Publication of CN103974712A publication Critical patent/CN103974712A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280027349.3A 2011-04-27 2012-04-27 治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法 Pending CN103974712A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711451914.XA CN108283712A (zh) 2011-04-27 2012-04-27 治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161479593P 2011-04-27 2011-04-27
US61/479,593 2011-04-27
US201161527744P 2011-08-26 2011-08-26
US61/527,744 2011-08-26
PCT/US2012/035547 WO2012149389A2 (en) 2011-04-27 2012-04-27 Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201711451914.XA Division CN108283712A (zh) 2011-04-27 2012-04-27 治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法

Publications (1)

Publication Number Publication Date
CN103974712A true CN103974712A (zh) 2014-08-06

Family

ID=47073094

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280027349.3A Pending CN103974712A (zh) 2011-04-27 2012-04-27 治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法
CN201711451914.XA Pending CN108283712A (zh) 2011-04-27 2012-04-27 治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201711451914.XA Pending CN108283712A (zh) 2011-04-27 2012-04-27 治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法

Country Status (13)

Country Link
US (4) US20140107037A1 (https=)
EP (2) EP2701721A4 (https=)
JP (1) JP6035326B2 (https=)
KR (5) KR20200043534A (https=)
CN (2) CN103974712A (https=)
AU (1) AU2012249397B2 (https=)
BR (1) BR112013027554A2 (https=)
CA (1) CA2834286A1 (https=)
EA (2) EA029999B1 (https=)
HK (1) HK1258231A1 (https=)
MX (1) MX357761B (https=)
SG (2) SG10202010665YA (https=)
WO (1) WO2012149389A2 (https=)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504670B2 (en) 2013-01-29 2016-11-29 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US9512133B2 (en) 2008-09-18 2016-12-06 Northwestern University NMDA receptor modulators and uses thereof
US9708335B2 (en) 2013-01-29 2017-07-18 Apytinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US9738650B2 (en) 2013-01-29 2017-08-22 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US9758525B2 (en) 2013-01-29 2017-09-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US9828384B2 (en) 2013-01-29 2017-11-28 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US9925169B2 (en) 2016-05-19 2018-03-27 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US9932347B2 (en) 2016-05-19 2018-04-03 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US10150769B2 (en) 2016-08-01 2018-12-11 Aptinyx Inc. Spiro-lactam NMDA modulators and methods of using same
US10918637B2 (en) 2016-08-01 2021-02-16 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US10961189B2 (en) 2016-08-01 2021-03-30 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US11028095B2 (en) 2016-08-01 2021-06-08 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
US11299495B2 (en) 2016-08-01 2022-04-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
WO2011100585A1 (en) 2010-02-11 2011-08-18 Joseph Moskal Secondary structure stabilized nmda receptor modulators and uses thereof
US9745342B2 (en) * 2013-10-28 2017-08-29 Naurex, Inc. NMDA receptor modulators and prodrugs, salts, and uses thereof
CN111920412A (zh) * 2013-12-13 2020-11-13 西北大学 治疗脑部病症或鉴定与其相关的生物标记的方法
CN105327349A (zh) * 2014-06-18 2016-02-17 上海翰森生物医药科技有限公司 Nmda受体拮抗剂的医药用途及其药物组合物
AU2015280108B2 (en) * 2014-06-23 2019-11-28 Naurex, Inc. Methods of treating or ameliorating migraine
CN108601814A (zh) * 2015-10-16 2018-09-28 西北大学 用于治疗精神分裂症、双相障碍、认知损害和重度抑郁障碍的非典型抗精神病药和nmda调节剂的药物组合
KR102415692B1 (ko) 2020-09-01 2022-07-05 건국대학교 글로컬산학협력단 시냅스 불균형 조절에 의한 발달장애 예방, 개선 또는 치료용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828318B2 (en) * 2000-07-25 2004-12-07 Vernalis Research Limited 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
CN1642547A (zh) * 2002-01-16 2005-07-20 恩多制药公司 治疗中枢神经系统障碍的药物组合物和方法
WO2010033757A1 (en) * 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
WO2011044089A2 (en) * 2009-10-05 2011-04-14 Joseph Moskal Methods of treating depression and other related diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
DE602006020353D1 (de) * 2005-03-24 2011-04-07 Univ Emory Progesterone Dosierungsanweisung in der Behandlung einer traumatischen Verletzung des Gehirns
WO2009105718A1 (en) * 2008-02-20 2009-08-27 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828318B2 (en) * 2000-07-25 2004-12-07 Vernalis Research Limited 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
CN1642547A (zh) * 2002-01-16 2005-07-20 恩多制药公司 治疗中枢神经系统障碍的药物组合物和方法
WO2010033757A1 (en) * 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
WO2011044089A2 (en) * 2009-10-05 2011-04-14 Joseph Moskal Methods of treating depression and other related diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GHANIZADEH A.等: "Targeting of glycine site on NMDA receptor as a possible new strategy for autism treatment", 《NEUROCHEMICAL RESEARCH》, vol. 36, no. 5, 6 January 2011 (2011-01-06), pages 922 - 923, XP019893970, DOI: 10.1007/s11064-010-0381-2 *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9802946B2 (en) 2008-09-18 2017-10-31 Northwestern University NMDA receptor modulators and uses thereof
US10906913B2 (en) 2008-09-18 2021-02-02 Northwestern University NMDA receptor modulators and uses thereof
US9512133B2 (en) 2008-09-18 2016-12-06 Northwestern University NMDA receptor modulators and uses thereof
US9828384B2 (en) 2013-01-29 2017-11-28 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US12167998B2 (en) 2013-01-29 2024-12-17 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam NMDA receptor modulators and uses thereof
US9738650B2 (en) 2013-01-29 2017-08-22 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US9758525B2 (en) 2013-01-29 2017-09-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US9579304B2 (en) 2013-01-29 2017-02-28 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US10441572B2 (en) 2013-01-29 2019-10-15 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US9504670B2 (en) 2013-01-29 2016-11-29 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US9708335B2 (en) 2013-01-29 2017-07-18 Apytinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US10052308B2 (en) 2013-01-29 2018-08-21 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US11077094B2 (en) 2013-01-29 2021-08-03 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US9512134B2 (en) 2013-01-29 2016-12-06 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US10441571B2 (en) 2013-01-29 2019-10-15 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US10253032B2 (en) 2013-01-29 2019-04-09 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US10273239B2 (en) 2013-01-29 2019-04-30 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US10316041B2 (en) 2013-01-29 2019-06-11 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US9925169B2 (en) 2016-05-19 2018-03-27 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US10195179B2 (en) 2016-05-19 2019-02-05 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US10196401B2 (en) 2016-05-19 2019-02-05 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US9932347B2 (en) 2016-05-19 2018-04-03 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US11376250B2 (en) 2016-08-01 2022-07-05 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US11512051B2 (en) 2016-08-01 2022-11-29 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US10150769B2 (en) 2016-08-01 2018-12-11 Aptinyx Inc. Spiro-lactam NMDA modulators and methods of using same
US11299495B2 (en) 2016-08-01 2022-04-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US11370790B2 (en) 2016-08-01 2022-06-28 Aptinyx Inc. Spiro-lactam NMDA modulators and methods of using same
US10961189B2 (en) 2016-08-01 2021-03-30 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US11427585B2 (en) 2016-08-01 2022-08-30 Aptinyx Inc. Spiro-lactam NMDA modulators and methods of using same
US11028095B2 (en) 2016-08-01 2021-06-08 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
US11530223B2 (en) 2016-08-01 2022-12-20 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US10918637B2 (en) 2016-08-01 2021-02-16 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US12157736B2 (en) 2016-08-01 2024-12-03 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam NMDA modulators and methods of using same
US12084444B2 (en) 2016-08-01 2024-09-10 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam NMDA modulators and methods of using same
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Also Published As

Publication number Publication date
WO2012149389A3 (en) 2014-05-08
US20190209642A1 (en) 2019-07-11
EA029999B1 (ru) 2018-06-29
HK1258231A1 (zh) 2019-11-08
KR20190037359A (ko) 2019-04-05
KR20140043078A (ko) 2014-04-08
EA201391581A1 (ru) 2014-05-30
AU2012249397B2 (en) 2017-03-30
SG10202010665YA (en) 2020-11-27
EP2701721A4 (en) 2015-12-16
CN108283712A (zh) 2018-07-17
KR20210046843A (ko) 2021-04-28
JP2014520072A (ja) 2014-08-21
EP3679931A3 (en) 2020-10-14
US20140107037A1 (en) 2014-04-17
KR20180095096A (ko) 2018-08-24
WO2012149389A2 (en) 2012-11-01
US20210169964A1 (en) 2021-06-10
SG194230A1 (en) 2013-12-30
CA2834286A1 (en) 2012-11-01
KR20200043534A (ko) 2020-04-27
JP6035326B2 (ja) 2016-11-30
EA201790653A1 (ru) 2017-07-31
US20170049845A1 (en) 2017-02-23
MX357761B (es) 2018-07-23
MX2013012526A (es) 2014-04-16
EP3679931A2 (en) 2020-07-15
BR112013027554A2 (pt) 2016-09-06
AU2012249397A1 (en) 2013-11-07
EP2701721A2 (en) 2014-03-05

Similar Documents

Publication Publication Date Title
CN103974712A (zh) 治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法
AU2018326768B2 (en) Novel uses of piperidinyl-indole derivatives
Brink et al. Tianeptine: a novel atypical antidepressant that may provide new insights into the biomolecular basis of depression
JP2018076332A (ja) （３ａＲ）−１，３ａ，８−トリメチル−１，２，３，３ａ，８，８ａ−ヘキサヒドロピロロ［２，３−ｂ］インドール−５−イルフェニルカルバメートの有効量およびその使用方法
Tucker et al. RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine
EP4116415A1 (en) Neurodegenerative disorders
US20240024304A1 (en) Methods of managing conditioned fear with neurokinin receptor antagonists
EP3965769B1 (en) Use of 2-phenyl-6-(1h-imidazol-1-yl)quinazoline for treating neurodegenerative diseases, preferably alzheimer's disease
CN110121361A (zh) 用于治疗运动神经元疾病的神经节苷脂代谢抑制剂
CN110719779A (zh) 包含非外消旋比例的(r)-地来西坦(1)和(s)-地来西坦(2)的协同组合物
US20180318379A1 (en) Inhibition of triggering receptor expressed on myeloid cells 1 (trem1) to treat central nervous system disorders
EP4554629A1 (en) Methods and formulations for gene therapy, and for combining gene therapy with ditpa treatment, of allan-herndon-dudley syndrome
HK40034037A (en) Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders
US20090221610A1 (en) Compositions and Methods for Treating Cognitive Disorders
Jack Jhamandas Glutamate system, amyloid [Beta] peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology
Orozco-Suárez et al. Epilepsy: Experimental and Human Studies
WO2017209027A1 (ja) オートファジー誘導剤
CA2968933C (en) Peptides for use in neurodegenerative disorders
HK40109116B (en) Novel uses of piperidinyl-indole derivatives
HK40022389B (en) Piperidinyl-indole derivatives for use in the treatment of c3 glomerulopathy
HK40022389A (en) Piperidinyl-indole derivatives for use in the treatment of c3 glomerulopathy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140806